n Europe for Venous Stasis Ulcers
Selected Abstract
RegeneRx's TB4 Subject of Phase II Clinical Trial In Europe for Venous Stasis Ulcers.
BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced a second Phase II clinical trial to test its drug, Thymosin beta 4 (TB4), for the treatment of venous stasis ulcers. I'm pleased to report we are clear to initiate our second Phase II dermal wound healing ... January 18, 2005; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
